Terms: = Breast cancer AND MDM2, HDM2, 4193, ENSG00000135679, HDMX, MGC71221, hdm2, Q00987
692 results:
1. Discovery of ganoderic acid A (GAA) PROTACs as mdm2 protein degraders for the treatment of breast cancer.
Li Y; Li G; Zuo C; Wang X; Han F; Jia Y; Shang H; Tian Y
Eur J Med Chem; 2024 Apr; 270():116367. PubMed ID: 38581732
[TBL] [Abstract] [Full Text] [Related]
2. Targeting G-rich sequence to regulate the transcription of murine double minute (MDM) genes in triple-negative breast cancers.
Feng Y; Xuan X; Hu Y; Lu J; Dong Z; Sun Z; Yao H; Hu L; Yin Q; Liu Y; Wang H
Eur J Med Chem; 2024 Mar; 267():116156. PubMed ID: 38295687
[TBL] [Abstract] [Full Text] [Related]
3. Identifying actionable druggable targets for breast cancer: Mendelian randomization and population-based analyses.
Zhang N; Li Y; Sundquist J; Sundquist K; Ji J
EBioMedicine; 2023 Dec; 98():104859. PubMed ID: 38251461
[TBL] [Abstract] [Full Text] [Related]
4. LC-HRMS Profiling and Cytotoxic Potential of Actinomycetes Associated with the Red Sea Soft Coral Sarcophyton glaucum: In vitro and In silico Studies.
El-Hawary SS; Hassan MHA; Hudhud AO; Al-Karmalawy AA; Mustafa M; Hamed EAE; Abdelmohsen UR; Mohammed R
Chem Biodivers; 2024 Mar; 21(3):e202301617. PubMed ID: 38193652
[TBL] [Abstract] [Full Text] [Related]
5. Gankyrin inhibits ferroptosis through the p53/SLC7A11/GPX4 axis in triple-negative breast cancer cells.
Lei M; Zhang YL; Huang FY; Chen HY; Chen MH; Wu RH; Dai SZ; He GS; Tan GH; Zheng WP
Sci Rep; 2023 Dec; 13(1):21916. PubMed ID: 38081931
[TBL] [Abstract] [Full Text] [Related]
6. C9orf142 transcriptionally activates MTBP to drive progression and resistance to CDK4/6 inhibitor in triple-negative breast cancer.
Liao L; Deng L; Zhang YL; Yang SY; Andriani L; Hu SY; Zhang FL; Shao ZM; Li DQ
Clin Transl Med; 2023 Nov; 13(11):e1480. PubMed ID: 38009308
[TBL] [Abstract] [Full Text] [Related]
7. Actinomycin D synergizes with Doxorubicin in triple-negative breast cancer by inducing P53-dependent cell apoptosis.
Yang H; Li S; Li W; Yang Y; Zhang Y; Zhang S; Hao Y; Cao W; Xu F; Wang H; Du G; Wang J
Carcinogenesis; 2024 Apr; 45(4):262-273. PubMed ID: 37997385
[TBL] [Abstract] [Full Text] [Related]
8. Immunoexpression of HER2 pathway related markers in HER2 invasive breast carcinomas treated with trastuzumab.
Franco AFDV; Malinverni ACM; Waitzberg AFL
Pathol Res Pract; 2023 Dec; 252():154917. PubMed ID: 37977031
[TBL] [Abstract] [Full Text] [Related]
9. Death-associated protein kinase 1 phosphorylates mdm2 and inhibits its protein stability and function.
Zhang M; Shui X; Zheng X; Lee JE; Mei Y; Li R; Tian Y; Zheng X; Wang Q; Wang L; Chen D; Zhang T; Kim BM; Kim J; Lee TH
Arch Pharm Res; 2023 Dec; 46(11-12):882-896. PubMed ID: 37804415
[TBL] [Abstract] [Full Text] [Related]
10. Atypical cystic hypersecretory lesions of the breast commonly harbour TP53 alterations.
Boyraz B; Sgroi DC; Iafrate AJ; Lerwill MF
Histopathology; 2023 Dec; 83(6):989-993. PubMed ID: 37771083
[TBL] [Abstract] [Full Text] [Related]
11. ZNF500 abolishes breast cancer proliferation and sensitizes chemotherapy by stabilizing P53 via competing with mdm2.
Ma X; Fan M; Yang K; Wang Y; Hu R; Guan M; Hou Y; Ying J; Deng N; Li Q; Jiang G; Zhang Y; Zhang X
Cancer Sci; 2023 Nov; 114(11):4237-4251. PubMed ID: 37700392
[TBL] [Abstract] [Full Text] [Related]
12. Pooled ctDNA analysis of MONALEESA phase III advanced breast cancer trials.
André F; Su F; Solovieff N; Hortobagyi G; Chia S; Neven P; Bardia A; Tripathy D; Lu YS; Lteif A; Taran T; Babbar N; Slamon D; Arteaga CL
Ann Oncol; 2023 Nov; 34(11):1003-1014. PubMed ID: 37673211
[TBL] [Abstract] [Full Text] [Related]
13. Sarcoma care in the era of precision medicine.
Wallander K; Öfverholm I; Boye K; Tsagkozis P; Papakonstantinou A; Lin Y; Haglund de Flon F
J Intern Med; 2023 Dec; 294(6):690-707. PubMed ID: 37643281
[TBL] [Abstract] [Full Text] [Related]
14. GSG2 facilitates the progression of human breast cancer through mdm2-mediated ubiquitination of E2F1.
Tang Y; Dai G; Yang Y; Liu H
J Transl Med; 2023 Aug; 21(1):523. PubMed ID: 37537694
[TBL] [Abstract] [Full Text] [Related]
15. P53 status, and G2/M cell cycle arrest, are determining factors in cell-death induction mediated by ELF-EMF in glioblastoma.
Mehdizadeh R; Madjid Ansari A; Forouzesh F; Shahriari F; Shariatpanahi SP; Salaritabar A; Javidi MA
Sci Rep; 2023 Jul; 13(1):10845. PubMed ID: 37407632
[TBL] [Abstract] [Full Text] [Related]
16. Identification of the Stapled α-Helical Peptide ATSP-7041 as a Substrate and Strong Inhibitor of OATP1B1 In Vitro.
Ishikawa R; Saito K; Misawa T; Demizu Y; Saito Y
Biomolecules; 2023 Jun; 13(6):. PubMed ID: 37371582
[TBL] [Abstract] [Full Text] [Related]
17. Clinical and Genomic Characteristics of Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic breast cancer Following Progression on Cyclin-Dependent Kinase 4 and 6 Inhibitors.
Rao X; Chen Y; Beyrer J; Nash Smyth E; Morato Guimaraes C; Litchfield LM; Bowman L; Lawrence GW; Aggarwal A; Andre F
Clin Cancer Res; 2023 Sep; 29(17):3372-3383. PubMed ID: 37289194
[TBL] [Abstract] [Full Text] [Related]
18. Identification of mdm2 as a prognostic and immunotherapeutic biomarker in a comprehensive pan-cancer analysis: A promising target for breast cancer, bladder cancer and ovarian cancer immunotherapy.
Zheng J; Miao F; Wang Z; Ma Y; Lin Z; Chen Y; Kong X; Wang Y; Zhuang A; Wu T; Li W
Life Sci; 2023 Aug; 327():121832. PubMed ID: 37276911
[TBL] [Abstract] [Full Text] [Related]
19. Effect of Smilax spp. and Phellinus linteus combination on cytotoxicity and cell proliferation of breast cancer cells.
Chalertpet K; Sangkheereeput T; Somjit P; Bankeeree W; Yanatatsaneejit P
BMC Complement Med Ther; 2023 Jun; 23(1):177. PubMed ID: 37264344
[TBL] [Abstract] [Full Text] [Related]
20. Extracellular and intracellular functions of coiled-coil domain containing 3.
Omari S; Lee H; Wang J; Zeng SX; Lu H
J Mol Cell Biol; 2023 Nov; 15(6):. PubMed ID: 37263799
[TBL] [Abstract] [Full Text] [Related]
[Next]
